267
Participants
Start Date
March 31, 2005
Primary Completion Date
April 30, 2007
Study Completion Date
April 30, 2007
RAD001, Letrozole 2.5mg
Letrozole 2.5mg
Roswell Park Cancer Institute, Buffalo
UPMC / Magee Womens Hospital, Pittsburgh
University of Miami, Miami
Investigative Clinical Research of Indiana, Indianapolis
University of Michigan, Ann Arbor
Loyola University Medical Center, Maywood
Ochsner Clinic Foundation, New Orleans
Highlands Oncology Group, Springdale
Breastlink Medical Group Inc., Long Beach
UCSF Breast Care Center, San Francisco
Novartis Investigative Site, Salzburg
Novartis Investigative Site, Vienna
Novartis Investigative Site, Wilrijk
Novartis Investigative Site, Natasha
Novartis Investigative Site, Winnipeg
Novartis Investigative Site, Besançon
Novartis Investigative Site, Bordeaux
Novartis Investigative Site, Montpellier
Novartis Investigative Site, Paris
Novartis Investigative Site, Saint-Herblain
Novartis Investigative Site, Berlin
Novartis Investigative Site, Erlangen
Novartis Investigative Site, Frankurt Am Main
Novartis Investigative Site, Jena
Novartis Investigative Site, Kiel
Novartis Investigative Site, München
Novartis Investigative Site, Regensburg
Novartis Investigative Site, Tübingen
Novartis Investigative Site, Florence
Novartis Investigative Site, Milan
Novartis Investigative Site, Naples
Novartis Investigative Site, Torino
Novartis Investigative Site, Chelyabinsk
Novartis Investigative Site, Kazan'
Novartis Investigative Site, Saint Petersburg
Novartis Investigative Site, Alicante
Novartis Investigative Site, Barcelona
Novartis Investigative Site, Córdoba
Novartis Investigative Site, Madrid
Novartis Investigative Site, Valencia
Novartis Investigative Site, Zaragoza
Novartis Investigative Site, Chelmsford
Novartis Investigative Site, Edinburgh
Novartis Investigative Site, Epping
Novartis Investigative Site, London
Novartis Investigative Site, Whittington
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY